Belgium’s deputy prime minister has called on the EU to deploy its Anti-Coercion Instrument against Washington’s most-favored-nation drug pricing policy, as eight member states weigh a joint pharmaceutical task force.

DRUG PRICING · PRICE REGULATION · OCTOBER 31, 2026 · EUROPE
Rarely does a health minister reach for trade law to defend a medicines budget. On October 29, 2026, Frank Vandenbroucke — Belgium’s deputy prime minister and health minister, and an economist by training — published a position paper through the Egmont Institute think tank calling on the European Union to ready its Anti-Coercion Instrument (ACI), the bloc’s so-called ‘trade bazooka,’ in response to Washington’s most-favored-nation (MFN) drug pricing policy, according to Politico. The paper was co-authored with his deputy head of cabinet, Gloria Ghéquière.
The MFN policy ties American drug prices to the lowest prices charged in a basket of wealthy countries, including France, Germany and Italy, per Politico. The US has already concluded MFN pricing agreements with 26 pharmaceutical companies, which have agreed to benchmark the prices of drugs supplied to Medicaid, the US federal-state health insurance programme for low-income people, according to the same report. The intended effect is for manufacturers to raise prices in third countries, lower their US prices, or both.
35%
Reuters reported in March 2026 data showing a 35% drop in European new drug launches, as companies sought more clarity on US most-favored-nation pricing before entering European markets.
A fiscal instrument, not just a pricing correction
Vandenbroucke’s paper surfaces a detail that reframes the policy’s logic. According to Politico, Pfizer’s MFN agreement includes a clause requiring it to share additional revenue from higher prices outside the US with the American government. ‘Higher foreign payments thus become a source of revenue for the American government itself,’ the authors write, as quoted by Politico. If other agreements carry similar clauses, Washington would have a direct fiscal incentive to sustain upward pressure on European prices.
A forecast cited in the paper sharpens the asymmetry: prices could triple in countries used as benchmarks, while US prices would fall by just 7.5% to 15%, per Politico. Vandenbroucke said the net effect would likely be an extreme increase in European drug prices — or the withdrawal of drugs from the market — while producing comparatively modest price cuts in the US. ‘The consequences would reach well beyond the medicines budget, putting pressure on the solidarity that universal insurance is designed to secure,’ the authors write, per Politico.
The US has also moved to bilateral pressure. In June 2026, the Office of the United States Trade Representative (USTR) launched a Section 301 investigation — a trade probe under the Trade Act of 1974 — into Germany’s alleged ‘persistent underpayment’ for innovative pharmaceuticals, according to Fierce Pharma. Germany had proposed cuts to its drug spending aiming for savings of 1.9 billion euros in 2027 as part of a broader healthcare reform plan, per the same report. Politico reports that the investigation could lead to additional tariffs exceeding the 15% ceiling agreed under the Turnberry trade deal of August 2025.
Member states divided on who should negotiate
At an informal meeting of EU health ministers in Dublin, ministers from Ireland, France, Germany, Italy, Denmark, Sweden, the Netherlands and Belgium discussed creating an EU-wide pharmaceutical task force to coordinate their response, according to Politico. EU Health Commissioner Oliver Varhelyi reportedly proposed that the European Commission negotiate directly with the US administration on MFN — a proposal health ministers unanimously rejected, arguing that the issue falls under national competence, according to Greek officials cited by Rapporteur, a European policy publication.
The ministers argued that any agreement negotiated at EU level could bind member states that lack the capacity to support its terms, per Rapporteur. An alternative — a member-state alliance negotiating directly with Washington — was floated in Dublin, but neither its format nor its objectives have been defined, and the proposal is expected to be examined ahead of the formal health ministers’ meeting in December, per Rapporteur.
Sweden’s Minister for Social Affairs and Public Health, Jakob Forssmed, acknowledged that medicine pricing is a national competence but stressed coordination. ‘We need to be generous with each other when it comes to intel on how this is affecting our markets and our introduction of medicines,’ he told Rapporteur ahead of the Dublin meeting. French Trade Minister Nicolas Forissier put the collective-action risk plainly: ‘If we don’t work together and act as a team, countries are inevitably tempted to go it alone,’ he told Politico.
The European Commission’s own summer analysis of MFN’s potential impact concluded that it was still too early to assess the policy’s full consequences, according to Rapporteur. Rainer Becker, of the Commission’s Directorate-General for Health and Food Safety, offered a measured reading at the European Health Forum in Gastein, Austria: ‘I think there’s some truth in it,’ he said of the rationale behind the policy, pointing to Canada’s introduction of reference pricing as a precedent. He flagged a key uncertainty: the effect on European prices and launch timing depends on what share of the US market is covered. ‘If 100% of the US market were affected by that policy, you would probably see different effects elsewhere in the world than if only a smaller part were affected,’ he said, per Rapporteur.
That uncertainty is already visible in company behaviour. Reuters reported in March 2026 that drugmakers were delaying some European launches, citing data showing a 35% drop in new drug launches in Europe, as companies sought clarity on US prices first. Eli Lilly Chief Executive Officer David Ricks, speaking on the company’s second-quarter 2025 earnings call, said he supported rebalancing pricing between the US and Europe but cautioned that ‘apples-to-apples comparisons of ex-factory pricing’ are ‘inaccurate and misleading,’ as reported by Fierce Pharma.
The ACI allows the EU to impose tariffs and restrictions on services in response to foreign threats to trade if backed by a qualified majority of member countries, per Politico. ‘The procedure is quite heavy, but already opening an examination would have an effect of its own,’ the paper argues. It also calls for the EU to be ready to suspend the tariff concessions granted under the Turnberry deal if the US imposes additional duties on European goods.
The counterargument to the ACI path is institutional. A qualified-majority requirement means member states with different fiscal exposures and different dependence on US trade must align — a coordination problem the Dublin meeting itself illustrated. Countries that can absorb higher medicine prices more easily may calculate that bilateral accommodation with Washington is less costly than a bloc-wide confrontation, which could fracture the alliance before it forms.
What to Watch
- Whether any move toward an ACI examination gains the backing of a qualified majority of member states, before or after the December health ministers’ meeting
- Germany’s final drug spending reform and whether the USTR Section 301 investigation escalates to additional tariffs
- The share of the US market ultimately covered by MFN agreements, which Becker identified as the key variable for European launch timing and prices
The Pfizer revenue-sharing clause may prove the most consequential detail in the Vandenbroucke paper. If other MFN agreements contain similar provisions, the policy is less a temporary negotiating posture than a self-reinforcing fiscal mechanism — one that gives the US government a standing interest in higher European drug prices, which would make the EU’s response a long-duration policy problem rather than a bilateral trade skirmish.
Most-Favored-Nation Pricing · Forecast Cited in the Vandenbroucke Paper
| United States | Benchmark countries | |
|---|---|---|
| Forecast price change | Fall of 7.5%–15% | Could triple |
Source: Politico, on the Vandenbroucke/Ghéquière paper (2026-10-29). 26 companies have concluded MFN agreements with the US, per Politico.
Why this is relevant
Patients
A forecast cited in the Vandenbroucke paper suggests prices in most-favored-nation (MFN) benchmark countries could triple, while Reuters reported data showing a 35% drop in European new drug launches as companies awaited clarity on US pricing.
Industry
With 26 companies in MFN agreements with the US, per Politico, manufacturers face pressure to raise prices in reference markets or delay launches there; a Pfizer clause shares revenue from higher non-US prices with the US government.
Payers
European national health systems face the prospect of higher benchmark-country prices under MFN dynamics, which Vandenbroucke argues would put pressure on the solidarity that universal insurance is designed to secure, per Politico.
Regulators
Belgium’s Frank Vandenbroucke has called for the EU to ready the Anti-Coercion Instrument (ACI), the US Trade Representative opened a Section 301 investigation into Germany’s drug spending in June, and the December health ministers’ meeting is the next scheduled point for a coordinated EU response.
Sources: Politico: Belgium’s deputy PM wants to use ‘trade bazooka’ on US over pharma threats · Rapporteur: EU capitals consider direct negotiations with the US over MFN · Fierce Pharma: US to investigate Germany’s proposed drug spending reforms · Reuters: Drugmakers delay some European launches with wary eye on Trump’s pricing policies · Fierce Pharma: Amid MFN talks, Lilly chief warns US adoption of international drug prices could bring ‘worst of two worlds’
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







